For anyone who missed the brilliant webinar hosted by Professor Annemeike Aartsma-Rus from 13th April 2024, this is the recording of her session. She …
Take part in a trial programme about behavioural and emotional difficulties
Andria Papageorgiou, postgraduate research student at The University of Surrey, is inviting you to take part in a 6 week programme for parents/carers …
Take part in a trial programme about behavioural and emotional difficultiesRead More
Introducing our Newest Trustee: Emma Simmonds
Introducing Our Newest Trustee: Emma Simmonds “On behalf of the Board of Trustees at Action Duchenne, I extend a warm welcometo Emma as our newest …
Join our NEW Online Support Groups
We decided our regular online support groups needed a bit of a re-think. To make sure we’ve got everyone covered, there are now going to be 4 …
Action Duchenne are seeking Trustees (volunteer roles)
Action Duchenne are seeking Trustees (volunteer roles) Trustee Action Duchenne are currently searching for strong individuals to join the …
Action Duchenne are seeking Trustees (volunteer roles)Read More
Action Duchenne is seeking a Chairperson (volunteer role)
Action Duchenne is seeking a Chairperson (volunteer role) ChairpersonAction Duchenne are currently searching for a strong individual to guide and …
Action Duchenne is seeking a Chairperson (volunteer role)Read More
NICE Publishes Draft Guidance on Vamorolone for the Treatment of Duchenne Muscular Dystrophy
We stand with the Duchenne community in expressing our disappointment regarding the National Institute for Health and Care Excellence's (NICE) recent …
FDA Approves Givinostat for the Treatment of Duchenne Muscular Dystrophy in the USA
Further to our previous article on the publication of the phase 3 EPIDYS trial positive results for Givinostat, a histone deacetylase (HDAC) inhibitor …
FDA Approves Givinostat for the Treatment of Duchenne Muscular Dystrophy in the USARead More
Results from Italfarmaco Pivotal Phase 3 EPIDYS Study of Givinostat in Duchenne Muscular Dystrophy (DMD) Published in The Lancet Neurology
We are thrilled to announce exciting new developments regarding the investigational drug Givinostat, after Italfarmaco S.p.A. announced today that the …
PepGen Receives UK CTA Clearance from MHRA to Begin CONNECT2-EDO51 Phase 2 Clinical Trial
PepGen, a biotech company developing innovative oligonucleotide therapies for severe neuromuscular and neurological diseases, has received approval …
PepGen Receives UK CTA Clearance from MHRA to Begin CONNECT2-EDO51 Phase 2 Clinical TrialRead More
PTC Community Statement on Translarna (Ataluren) Market Authorisation in the European Union and Great Britain
PTC has provided a community statement regarding the recently decision by the CHMP/EMA to not renew the marketing authorisation for Translarna …
Annual General Meeting 2024
Annual General Meeting 2024 The Trustees of Action Duchenne would like to express their gratitude for the continued support from the Duchenne …